Lv4
488 积分 2023-02-28 加入
Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer
19天前
已关闭
Considerations for Clinical Trial Design in Relapsed and Refractory Osteosarcoma: An FDA Symposium
1个月前
已完结
LRRC15 antibody‐drug conjugates show promise as osteosarcoma therapeutics in preclinical studies
1个月前
已完结
Expression and clinical implications of leucine‐rich repeat containing 15 (LRRC15) in osteosarcoma
1个月前
已完结
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
1个月前
已完结
Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
1个月前
已完结
Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach
1个月前
已完结
The design of chronic toxicology studies of monoclonal antibodies: Implications for the reduction in use of non-human primates
1个月前
已完结
Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate?
1个月前
已完结
An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates
1个月前
已完结
皖公网安备34019202002308
